Multiple media reports say that U.S. pharmaceutical giant Johnson & Johnson (JNJ) is planning to buy biotechnology firm Ollin Biosciences for up to $3.4 billion U.S.
Based in Austin, Texas, privately held Ollin Biosciences develops therapies for treating eye diseases.
Media reports say that Johnson & Johnson could pay $2.2 billion U.S. in cash upfront and another $1.2 ?billion U.S. in future milestone payments to acquire Ollin Biosciences.
A deal between Johnson & Johnson and Ollin could be announced later on Nov. 16.
Ollin last raised $330 million ?U.S. in June of this year to advance its study of drug OLN324, which is used to treat diabetic macular edema (DME) and macular degeneration, two leading causes of vision loss.
The purchase of Ollin Biosciences would continue an acquisition streak for Johnson & Johnson.
The company acquired biotech Firefly Bio for $1 billion U.S. in cash earlier this year as it looked to expand its pipeline of cancer treatments.
In 2025, Johnson & Johnson bought drugmaker Intra-Cellular Therapies for $14.6 billion U.S. to help boost its presence in the market for neurological disorder treatments.
JNJ stock has risen 43% in the past 12 months to trade at $285.75 U.S. per share.
Related Stories